The main findings of this study were: (1) PELP1 was highly expressed in non-small lung cancer and its expression has been correlated with histotype, EGFR status, smoking status, and sex. PELP1 was not found to associate with survival of patients with lung cancer. (2). Knockdown of the expression of PELP1 significantly inhibited the proliferation and invasion of the lung adenocarcinoma cells. (3) Silencing PELP1 downregulate MAPK signal pathway and upregulate the expression of RB1. (4) PELP1 knockdown increased the sensitivity of lung adenocarcinoma cell to the TKI drug Gefitinib. (5) Our study revealed the whole genome transcription profile of the PELP1 acting on lung cancer cells. Generally, this work demonstrated that PELP1 plays important role in lung cancer cell proliferation, invasion, metastasis, and drug resistance which suggested the possibility of PELP1 as a potential therapeutic target.
[1]. Rebecca L.Siegel, Kimberly D.Miller, Ahmedin Jemal. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7–34.
[2]. World Health Organization. Global health estimates 2016: Deaths by Cause, Age, Sex, by country and by region, 2000–2016. Geneva, 2018.
[3]. L. Esposito, D. Conti, R. Ailavajhala, N. Khalil, et al. Lung cancer: are we up to the challenge? Curr. Genomics. 2010; 11:513–518.
[4]. travis WD, Brambilla E, Noguchi M, et al. international association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244 − 85.
[5]. United states public health service office of the surgeon general and national center for chronic disease prevention and health promotion office on smoking and health the health consequences of smoking- 50 years of progress: a report of the surgeon general. U.S. department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health 2014.
[6]. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England journal of medicine. 2004;350(21):2129-39.
[7]. Paez JG, Janner PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
[8]. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small -cell lung cancer with mutated EGFR. New England Journal of Medicine. 2010;362(25):2380–2388.
[9]. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine. 2009;361(10):947–957.
[10]. Diana C.M, Hsiao-Wang Chen, Michael C.F, et al. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids.2007;72(2):135 − 43.
[11]. Girard BJ, Daniel AR, Lange CA, et al. PELP1: a review of PELP1 interactions, signaling, and biology. Mol Cell Endocrinol. 2014; 382:642–651.
[12]. Brann DW, Zhang QG, Wang RM, Mahesh VB, Vadlamudi RK. PELP1-a novel estrogen receptor interacting protein. Mol Cell Endocrinol. 2008; 290:2–7.
[13]. Vadlamudi RK, Wang RA, Mazumdar A, et al. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 2001; 276:38272–38279.
[14]. Monica Mann, Valerie Cortez, Ratna Vadlamudi. PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis. 2013;34(7):1468–1475.
[15]. Young Bong Choi, Jin Kyoung Ko, Jaekyoon Shin. The transcriptional corepressor, PELP1, Recruits HDAC2 and masks histones using two separate domains. The journal of biological chemistry. 2004:279(49):50930-41.
[16]. Castle CD, Cassimere EK, Denicourt C. LAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesis. Mol Biol Cell. 2012; 23:716–728.
[17]. Finkbeiner E, Haindl M, Muller S. The SUMO system controls nucleolar partitioning of a novel mammalian ribosome biogenesis complex. EMBO J. 2011; 30:1067–1078.
[18]. Gonugunta VK, Nair BC, Rajhans R, Sareddy GR, Nair SS, Vadlamudi RK. Regulation of rDNA transcription by proto-oncogene PELP1. PLoS One. 2011; 6: e21095.
[19]. Xingen Wang, Julia Y.S Tsang, Michelle A Lee, et al. the clinical value of pelp1 for breast cancer: a comparison with multiple cancers and analysis in breast cancer subtypes. Cancer res. Treat. 2019:51(2),706–717.
[20]. Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR, Broaddus RR, Vadlamudi RK. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res. 2008; 68:4902–4909.
[21]. Cortez V, Samayoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma. Cancer Res. 2014; 74:7395–7405.
[22]. Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, Ellis IO. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat. 2010; 120:603–612.
[23]. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis. Clin Cancer Res. 2011; 17:2250–2259.
[24]. Rajhans R, Nair S, Holden AH, et al. oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine- rich protein 1/ modulator of the nongenomic actions of the estrogen receptor. Cancer Res. 2007 Jun 1;67(11):5505-12.
[25]. Cortez V, Samayoa C, Zamora A, et al. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma. Cancer Res. 2014,15;74(24):7395 − 405.
[26]. Habashy HO, Powe DG, Rakha EA, et al. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat. 2010,120(3):603 − 12.
[27]. Kefalopoulou Z, Tzelepi V, Zolota V, et al. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. J Neurooncol. 2012 Jan;106(1):23–31.
[28]. Nair SS, Guo Z, Mueller JM, et al. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol. 2007 Mar;21(3):613 − 24.
[29]. Aust S, Horak P, Pils D, et al. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer. 2013, (14)13:115.
[30]. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, et al. Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations. Cell Oncol. 2009;31(3):235 − 47.
[31] Rajib Rajhans, Sujit Nair, Alan H.Holden, et al. oncogenic potential of the nuclear receptor coregulator proline- glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer research. 2007;67(11):5505–5512.
[32] Jing wan, Xiaomao Li. Pelp1/mnar suppression inhibits proliferation and metastasis of endometrial carcinoma cells. Oncology reports. 2012;28: 2035–2042.
[33]. Roy, S., Chakravarty, D., Cortez, V., De Mukhopadhyay, K., Bandyopadhyay, A., Ahn, J.M., Raj, G.V., Tekmal, R.R., Sun, L., Vadlamudi, R.K., 2012. Significance of PELP1 in ER-negative breast cancer metastasis. Mol. Cancer Res. 10, 25–33.
[34]. Nair BC, Nair SS, Chakravarty D, et al. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res. 2010 Sep 15;70(18):7166-75.
[35]. Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res. 2005 1;65(17):7724-32.
[36]. Rayala SK, Hollander Pd, Balasenthil S, et al. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem. 2006 17;281(7):4395 − 403.
[37] Diana C.Marquez-Garban, Hsiao-Wang Chen, Michael C.fishbein, et al. estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids.2007;72:135–143.
[38] Jatin K.Nagpal, Sujit Nair, Dimple Chakravarty, et al. growth factor regulation of estrogen receptor coregulator pelp1 functions via protein kinase a pathway. Mol cancer Res. 2008;6(5):851–861.
[39]. Yunxiang Zhao, Ning Gao, Xinyun Li, et al. identifying candidate genes associated with sperm morphology abnormalities using weighted single-step GWAS in a Duroc boar population. Theriogenology. 2020; 141:9–15.